Big Time Small-Time DicksWelcome to Big Time Small-Time Dicks, a regular column on The Slot that explores local politicians, small-town scandals, and everything else making life miserable on a local level.
Big Time Small-Time DicksWelcome to Big Time Small-Time Dicks, a regular column on The Slot that explores local politicians, small-town scandals, and everything else making life miserable on a local level.
SAN DIEGO, Jan. 31, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento")announcedtodayadditional positiveresultsfrom itsPhase 1bstudy ofhumanallogeneicadipose-derivedmesenchymal stemcells(COVI-MSC)forpatients suffering from COVID-19-induced acute respiratory distress (ARD)oracute respiratory distress syndrome (ARDS). Thisongoingstudy (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy ofCOVI-MSCsadministered every other day for three infusions for a total of 1 x 106cells/kg.
SAN DIEGO, Jan. 31, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.(Nasdaq: SRNE, "Sorrento")announcedtodayadditional positiveresultsfrom itsPhase 1bstudy ofhumanallogeneicadipose-derivedmesenchymal stemcells(COVI-MSC)forpatients suffering from COVID-19-induced acute respiratory distress (ARD)oracute respiratory distress syndrome (ARDS). Thisongoingstudy (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy ofCOVI-MSCsadministered every other day for three infusions for a total of 1 x 106cells/kg
SAN DIEGO - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, 'Sorrento') announced today additional positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg.
SAN DIEGO - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, 'Sorrento') announced today additional positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg.
Cell bank firm Rooster Bio has teamed with Sartorius to find ways of scaling-up production of stem cell-based regenerative therapies. The collaboration will combine Roosters human mesenchymal stem/stromal cell (hMSC) working cell banks and media systems with Sartorius single-use manufacturing tech, process control software and analysis tools.
Request Download SampleAsk For Discount Company Profile New Jersey, United States,- Stem Cell Therapy Market Report gives a detailed analysis of the market. After a detailed examination of the current trends, the report shares the details around the factors fueling the markets momentum
BrainStorm Cell Therapeutics has announced that its NurOwn (MSC-NTF cell) derived exosomes provided significant improvement in lung function and histology in an acute respiratory distress syndrome (ARDS) mouse model, in a preclinical study. Mesenchymal stem cell (MSC)-derived exosomes can penetrate deep into tissues and deliver immunomodulatory molecules effectively
Image: Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine (Photo courtesy of University of Miami Health System) Researchers at the University of Miami Miller School of Medicine (Miami, FL, USA) who led the study believe that treating COVID-19 with mesenchymal stem cells makes sense. Mesenchymal cells not only help correct immune and inflammatory responses that go awry, they also have antimicrobial activity and have been shown to promote tissue regeneration
Bone Therapeutics, a cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Rigenerand SRL, a biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, have signed an agreement for a process development partnership.Allogeneic mesenchymal stem cell (MSC) therapies are currently being developed at a fast pace and are evaluated in numerous clinical studies covering diverse therapeutic areas such as bone and cartilage conditions, liver, cardiovascular and autoimmune diseases in which MSCs could have a significant positive effect.Advances in process development to scale up these therapies could have major impacts for both their approval and commercial viability. This will be essential to bring these therapies to market to benefit patients as quickly as possible, said Miguel Forte, chief executive officer, Bone Therapeutics
Recent Comments